Analyst firms · Argus Research · ELV
Argus Research ELV price target and rating history
Elevance Health Inc. (ELV) · Health Care
Argus Research rates Elevance Health Inc. (ELV) Hold with a $450 price target, as of its latest action on Jul 21, 2025. It has published 3 rating actions on ELV since October 2024, including 1 upgrade and 2 downgrades. Across 5 firms with a ELV price target in the last 12 months, the median target is $425.
- Current rating
- Hold
- Price target
- $450
- Median target, all firms
- $425
- Actions on ELV
- 3
Every Argus Research rating on ELV
- Jul 21, 2025
- Mar 17, 2025
- Oct 18, 2024
How other firms rate ELV
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Deutsche Bank | Buy | $498 | May 20, 2026 |
| BofA Securities | Buy | $435 | Apr 29, 2026 |
| Evercore ISI | In-line | $345 | Apr 8, 2026 |
| RBC Capital Markets | Sector Perform | $358 | Feb 3, 2026 |
| Wolfe Research | Outperform | $425 | Jan 8, 2026 |
Questions about Argus Research and ELV
- What is Argus Research's price target for ELV?
- Argus Research's latest stated price target for Elevance Health Inc. (ELV) is $450, from its action on Mar 17, 2025.
- What is Argus Research's rating on ELV?
- Argus Research rates ELV Hold, a neutral rating, as of Jul 21, 2025.
- When did Argus Research last change its view on ELV?
- On Jul 21, 2025, Argus Research downgrades to Hold from Buy.
- How does Argus Research's ELV target compare with other analysts?
- Across 5 firms with a ELV price target in the last 12 months, the median target is $425.
More ELV rating histories
All Argus Research ratingsELV news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.